Viking Therapeutics (VKTX) Reports In-Line Q4 EPS

Viking Therapeutics (NASDAQ: VKTX) reported Q4 EPS of ($0.15), in-line with the analyst estimate of ($0.15).

"2020 was a strong and productive year for Viking," stated Brian Lian, Ph.D., chief executive officer of Viking. "Despite the challenges posed by the global pandemic, we continued to open clinical sites and proceed with enrollment in our 52-week Phase 2b VOYAGE trial evaluating VK2809 in patients with NASH and fibrosis. Importantly, in the face of a COVID-19 resurgence in recent months, the majority of our U.S. sites remain open, and we continue to add both U.S. and ex-U.S. sites. We currently expect to complete enrollment in the second half of 2021. With respect to our VK0214 program for X-linked adrenoleukodystrophy, we made excellent progress in 2020 and were pleased to announce last fall the initiation of a first-in-human study with this important molecule. Pending successful completion of the Phase 1 single ascending and multiple ascending dose study, we plan to initiate a Phase 1b trial in X-ALD patients. On the personnel side, we recently announced the appointment of Marianne Mancini to the position of COO and Greg Zante to CFO. Both Marianne and Greg have exhibited strong leadership in the management of Viking's clinical operations and financial strategy, respectively, and we are pleased to appoint them to these roles within the organization."

For earnings history and earnings-related data on Viking Therapeutics (VKTX) click here.

You May Also Be Interested In

• Equifax (EFX) shares tumble as Q2, full-year guidance falls short
• CSX Corp. (CSX) Tops Q1 EPS by 1c
• Monarch Casino & Resort (MCRI) Misses Q1 EPS by 4c